Category Archives: Global
European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). Only 22% of physicians consider themselves “very familiar” with this category of medicines, and while a majority (54%) have a “basic understanding” of biosimilars, 24% of participants could not define or have not heard about […]
Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.
By Guest Blogger | Published: March 14, 2014
The European pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery, writes Faiz Kermani. The European pharmaceutical industry accounts for nearly 40% of the global industry’s R&D investment. Although companies are responding to current pressures by closing R&D sites, they still need to support their ongoing drug-development projects […]
By Julian Upton | Published: March 13, 2014
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign calling for an integrated life sciences strategy for the EU. The #HealthyEU Health and Growth campaign will outline the opportunities and threats faced by patients and the healthcare sector today, and provide evidence and facts to inform healthcare debates in the run […]